Provided by Tiger Trade Technology Pte. Ltd.

Filana Therapeutics

0.9650
+0.07908.92%
Post-market: 0.9500-0.0150-1.55%19:30 EDT
Volume:2.80M
Turnover:2.75M
Market Cap:46.62M
PE:-1.10
High:1.03
Open:1.00
Low:0.9300
Close:0.8860
52wk High:4.98
52wk Low:0.6701
Shares:48.31M
Float Shares:47.32M
Volume Ratio:1.96
T/O Rate:5.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8752
EPS(LYR):-1.8836
ROE:-55.78%
ROA:-7.14%
PB:0.73
PE(LYR):-0.51

Loading ...

Company Profile

Company Name:
Filana Therapeutics
Exchange:
NASDAQ
Establishment Date:
1998
Employees:
19
Office Location:
6801 N. Capital of Texas Highway,Building 1,Austin,Texas,United States
Zip Code:
78731
Fax:
- -
Introduction:
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.

Directors

Name
Position
Claude Nicaise
Chairman of the Board and Director
Richard J. Barry
Chief Executive Officer and Director and President
Dawn Carter Bir
Director
Michael J. O'donnell
Director
Patrick J. Scannon
Director
Pierre Gravier
Director
Robert Anderson
Director
Robert Z. Gussin
Director

Shareholders

Name
Position
Richard J. Barry
Chief Executive Officer and Director and President
Eric J. Schoen
Chief Financial Officer
R. Christopher Cook
Chief Operating and Legal Officer